Cardiovascular Gene Therapy: Past, Present, and Future

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1095-1106

  Ylä Herttuala, Seppo ^a,b   Baker, Andrew H ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

cardiovascular gene therapy; clinical trials; endpoints; heart failure; hyperlipidemias; ischemia; trial design

Indexed keywords

FIBROBLAST GROWTH FACTOR 4; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SCATTER FACTOR; VASCULOTROPIN D; FGF4 PROTEIN, HUMAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMID; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG APPROVAL; GENE EXPRESSION; GENE VECTOR; GENETICS; HISTORY; HUMAN ADENOVIRUS C; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PROCEDURES; TRENDS;

ADENOVIRUSES, HUMAN; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; FIBROBLAST GROWTH FACTOR 4; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INJECTIONS, INTRAMUSCULAR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85017348801     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.027     Document Type: Review

References (84)

1. 1 Nabel, E.G., Plautz, G., Nabel, G.J., Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249 (1990), 1285–1288.
2. 2 Grossman, M., Rader, D.J., Muller, D.W., Kolansky, D.M., Kozarsky, K., Clark, B.J. 3rd, Stein, E.A., Lupien, P.J., Brewer, H.B. Jr., Raper, S.E., et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1 (1995), 1148–1154.
3. 3 Isner, J.M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., Symes, J.F., Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348 (1996), 370–374.
4. 4 Laitinen, M., Mäkinen, K., Manninen, H., Matsi, P., Kossila, M., Agrawal, R.S., Pakkanen, T., Luoma, J.S., Viita, H., Hartikainen, J., et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum. Gene Ther. 9 (1998), 1481–1486.
5. 5 Hulot, J.S., Ishikawa, K., Hajjar, R.J., Gene therapy for the treatment of heart failure: promise postponed. Eur. Heart J. 37 (2016), 1651–1658.
6. 6 Ylä-Herttuala, S., Bridges, C., Katz, M.G., Korpisalo, P., Angiogenic gene therapy in cardiovascular diseases: dream or vision?. Eur. Heart J., 2017, 2017, 10.
7. 7 Ylä-Herttuala, S., Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther. 20 (2012), 1831–1832.
8. ΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients. A phase I/IIa study with one year follow-up. Submitted.
9. 9 Hassinen, I., Kivelä, A., Hedman, A., Saraste, A., Knuuti, J., Hartikainen, J.E., Ylä-Herttuala, S., Intramyocardial gene therapy directed to hibernating heart muscle using a combination of electromechanical mapping and positron emission tomography. Hum. Gene Ther. 27 (2016), 830–834.
10. 10 Ylä-Herttuala, S., Alitalo, K., Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9 (2003), 694–701.
11. 11 Henry, T.D., Satran, D., Jolicoeur, E.M., Treatment of refractory angina in patients not suitable for revascularization. Nat. Rev. Cardiol. 11 (2014), 78–95.
12. 12 Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marban, E., Assmus, B., Henry, T.D., Traverse, J.H., et al., ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 116 (2015), 1346–1360.
13. 13 Banovic, M., Loncar, Z., Behfar, A., Vanderheyden, M., Beleslin, B., Zeiher, A., Metra, M., Terzic, A., Bartunek, J., Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res. Ther., 6, 2015, 159.
14. 14 Kastrup, J., Jørgensen, E., Rück, A., Tägil, K., Glogar, D., Ruzyllo, W., Bøtker, H.E., Dudek, D., Drvota, V., Hesse, B., et al., Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45 (2005), 982–988.
15. 15 Hedman, M., Hartikainen, J., Syvänne, M., Stjernvall, J., Hedman, A., Kivelä, A., Vanninen, E., Mussalo, H., Kauppila, E., Simula, S., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003), 2677–2683.
16. 16 Stewart, D.J., Hilton, J.D., Arnold, J.M., Gregoire, J., Rivard, A., Archer, S.L., Charbonneau, F., Cohen, E., Curtis, M., Buller, C.E., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 13 (2006), 1503–1511.
17. 17 Stewart, D.J., Kutryk, M.J.B., Fitchett, D., Freeman, M., Camack, N., Su, Y., Siega, A.D., Bilodeau, L., Burton, J.R., Proulx, G., et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 17 (2009), 1109–1115.
18. 18 Kastrup, J., Jørgensen, E., Fuchs, S., Nikol, S., Bøtker, H.E., Gyöngyösi, M., Glogar, D., Kornowski, R., A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 6 (2011), 813–818.
19. 19 Ripa, R.S., Wang, Y., Jørgensen, E., Johnsen, H.E., Hesse, B., Kastrup, J., Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27 (2006), 1785–1792.
20. 20 Corautus Genetics (2006). Corautus announces termination of patient enrollment in GENASIS severe angina clinical trial. http://www.corautus.com.
21. 21 Rosengart, T.K., Lee, L.Y., Patel, S.R., Sanborn, T.A., Parikh, M., Bergman, G.W., Hachamovitch, R., Szulc, M., Kligfield, P.D., Okin, P.M., et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100 (1999), 468–474.
22. 22 Kilian, E.G., Sadoni, S., Vicol, C., Kelly, R., van Hulst, K., Schwaiger, M., Kupatt, C., Boekstegers, P., Pillai, R., Channon, K., et al. Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting. - A multicenter phase I and safety study -. Circ. J. 74 (2010), 916–924.
23. 23 Hedman, M., Muona, K., Hedman, A., Kivelä, A., Syvänne, M., Eränen, J., Rantala, A., Stjernvall, J., Nieminen, M.S., Hartikainen, J., Ylä-Herttuala, S., Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 16 (2009), 629–634.
24. 24 Rosengart, T.K., Bishawi, M.M., Halbreiner, M.S., Fakhoury, M., Finnin, E., Hollmann, C., Shroyer, A.L., Crystal, R.G., Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum. Gene Ther. 24 (2013), 203–208.
25. 25 Muona, K., Mäkinen, K., Hedman, M., Manninen, H., Ylä-Herttuala, S., 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther. 19 (2012), 392–395.
26. 26 Koponen, J.K., Kekarainen, T., Heinonen, S.E., Laitinen, A., Nystedt, J., Laine, J., Ylä-Herttuala, S., Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol. Ther. 15 (2007), 2172–2177.
27. 27 Kaminsky, S.M., Quach, L., Chen, S., Pierre-Destine, L., Van de Graaf, B., Monette, S., Rosenberg, J.B., De, B.P., Sondhi, D., Hackett, N.R., et al. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum. Gene Ther. Clin. Dev. 24 (2013), 38–46.
28. 28 Henry, T.D., Grines, C.L., Watkins, M.W., Dib, N., Barbeau, G., Moreadith, R., Andrasfay, T., Engler, R.L., Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50 (2007), 1038–1046.
29. 29 Kaski, J.C., Consuegra-Sanchez, L., Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin. Biol. Ther. 13 (2013), 1749–1753.
30. 30 Yang, Z.J., Zhang, Y.R., Chen, B., Zhang, S.L., Jia, E.Z., Wang, L.S., Zhu, T.B., Li, C.J., Wang, H., Huang, J., et al. Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol. Biol. Rep. 36 (2009), 1323–1329.
31. 31 Kim, J.S., Hwang, H.Y., Cho, K.R., Park, E.A., Lee, W., Paeng, J.C., Lee, D.S., Kim, H.K., Sohn, D.W., Kim, K.B., Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther. 20 (2013), 717–722.
32. 32 Turunen, M.P., Lehtola, T., Heinonen, S.E., Assefa, G.S., Korpisalo, P., Girnary, R., Glass, C.K., Väisänen, S., Ylä-Herttuala, S., Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ. Res. 105 (2009), 604–609.
33. 33 Ziegler, T., Hinkel, R., Stöhr, A., Eschenhagen, T., Laugwitz, K.L., le Noble, F., David, R., Hansen, A., Kupatt, C., Thymosin β4 Improves Differentiation and Vascularization of EHTs. Stem Cells Int., 2017, 2017, 6848271.
34. 34 Hinkel, R., Trenkwalder, T., Kupatt, C., Molecular and cellular mechanisms of thymosin β4-mediated cardioprotection. Ann. N Y Acad. Sci. 1269 (2012), 102–109.
35. 35 Smart, N., Bollini, S., Dubé, K.N., Vieira, J.M., Zhou, B., Davidson, S., Yellon, D., Riegler, J., Price, A.N., Lythgoe, M.F., et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 474 (2011), 640–644.
36. 36 Henri, O., Pouehe, C., Houssari, M., Galas, L., Nicol, L., Edwards-Lévy, F., Henry, J.P., Dumesnil, A., Boukhalfa, I., Banquet, S., et al. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. Circulation 133 (2016), 1484–1497 discussion 1497.
37. 37 Beltrami, C., Besnier, M., Shantikumar, S., Shearn, A.I., Rajakaruna, C., Laftah, A., Sessa, F., Spinetti, G., Petretto, E., Angelini, G.D., Emanueli, C., Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis. Mol. Ther. 25 (2017), 679–693.
38. 38 Wang, C., Zhang, C., Liu, L., A, X., Chen, B., Li, Y., Du, J., Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury. Mol. Ther. 25 (2017), 192–204.
39. 39 Hammer, A., Steiner, S., Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Vasa 42 (2013), 331–339.
40. 40 Mäkinen, K., Manninen, H., Hedman, M., Matsi, P., Mussalo, H., Alhava, E., Ylä-Herttuala, S., Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 6 (2002), 127–133.
41. 41 Kusumanto, Y.H., van Weel, V., Mulder, N.H., Smit, A.J., van den Dungen, J.J.A.M., Hooymans, J.M., Sluiter, W.J., Tio, R.A., Quax, P.H., Gans, R.O., et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 17 (2006), 683–691.
42. 42 Rajagopalan, S., Mohler, E.R. 3rd, Lederman, R.J., Mendelsohn, F.O., Saucedo, J.F., Goldman, C.K., Blebea, J., Macko, J., Kessler, P.D., Rasmussen, H.S., Annex, B.H., Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003), 1933–1938.
43. 43 Deev, R.V., Bozo, I.Y., Mzhavanadze, N.D., Voronov, D.A., Gavrilenko, A.V., Chervyakov, Y.V., Staroverov, I.N., Kalinin, R.E., Shvalb, P.G., Isaev, A.A., pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia. J. Cardiovasc. Pharmacol. Ther. 20 (2015), 473–482.
44. 44 Nikol, S., Baumgartner, I., Van Belle, E., Diehm, C., Visoná, A., Capogrossi, M.C., Ferreira-Maldent, N., Gallino, A., Wyatt, M.G., Wijesinghe, L.D., et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16 (2008), 972–978.
45. 45 Belch, J., Hiatt, W.R., Baumgartner, I., Driver, I.V., Nikol, S., Norgren, L., Van Belle, E., TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377 (2011), 1929–1937.
46. 46 Yonemitsu, Y., Matsumoto, T., Maehara, Y., Gene Therapy for peripheral arterial disease using Sendai Virus vector: from preclinical studies to the Phase I/IIa clinical trial. Nagai, Y., (eds.) Sendai Virus Vector, First Edition, 2013, Springer, Japan, 183–201.
47. 47 Grossman, P.M., Mendelsohn, F., Henry, T.D., Hermiller, J.B., Litt, M., Saucedo, J.F., Weiss, R.J., Kandzari, D.E., Kleiman, N., Anderson, R.D., et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am. Heart J. 153 (2007), 874–880.
48. 48 Creager, M.A., Olin, J.W., Belch, J.J.F., Moneta, G.L., Henry, T.D., Rajagopalan, S., Annex, B.H., Hiatt, W.R., Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 124 (2011), 1765–1773.
49. 49 Ylä-Herttuala, S., Rissanen, T.T., Vajanto, I., Hartikainen, J., Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 49 (2007), 1015–1026.
50. 50 Dragneva, G., Korpisalo, P., Ylä-Herttuala, S., Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis. Model. Mech. 6 (2013), 312–322.
51. 51 Flugelman, M.Y., Halak, M., Yoffe, B., Schneiderman, J., Rubinstein, C., Bloom, A.I., Weinmann, E., Goldin, I., Ginzburg, V., Mayzler, O., et al. Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia. Mol. Ther. 25 (2017), 816–825.
52. 52 Vajanto, I., Korpisalo, P., Karjalainen, J., Hakala, T., Mäkinen, K., Ylä-Herttuala, S., Antegrade flow and peripheral resistance determine the level of endogenous arteriogenesis in patients with superficial femoral artery occlusion. Eur. J. Clin. Invest. 39 (2009), 1048–1054.
53. 53 Powell, R.J., Simons, M., Mendelsohn, F.O., Daniel, G., Henry, T.D., Koga, M., Morishita, R., Annex, B.H., Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118 (2008), 58–65.
54. 54 Shigematsu, H., Yasuda, K., Iwai, T., Sasajima, T., Ishimaru, S., Ohashi, Y., Yamaguchi, T., Ogihara, T., Morishita, R., Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 17 (2010), 1152–1161.
55. 55 Halonen, P.J., Nurro, J., Kuivanen, A., Ylä-Herttuala, S., Current gene therapy trials for vascular diseases. Expert Opin. Biol. Ther. 14 (2014), 327–336.
56. 56 Greenberg, B., Butler, J., Felker, G.M., Ponikowski, P., Voors, A.A., Desai, A.S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A.R., et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387 (2016), 1178–1186.
57. 57 Ylä-Herttuala, S., Gene Therapy for Heart Failure: Back to the Bench. Mol. Ther. 23 (2015), 1551–1552.
58. 58 Chung, E.S., Miller, L., Patel, A.N., Anderson, R.D., Mendelsohn, F.O., Traverse, J., Silver, K.H., Shin, J., Ewald, G., Farr, M.J., et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur. Heart J. 36 (2015), 2228–2238.
59. 59 Karpanen, T., Bry, M., Ollila, H.M., Seppänen-Laakso, T., Liimatta, E., Leskinen, H., Kivelä, R., Helkamaa, T., Merentie, M., Jeltsch, M., et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ. Res. 103 (2008), 1018–1026.
60. 60 Lähteenvuo, J.E., Lähteenvuo, M.T., Kivelä, A., Rosenlew, C., Falkevall, A., Klar, J., Heikura, T., Rissanen, T.T., Vähäkangas, E., Korpisalo, P., et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 119 (2009), 845–856.
61. 61 Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., van Meeteren, L.A., Samen, E., Lu, L., Vanwildemeersch, M., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464 (2010), 917–921.
62. 62 Woitek, F., Zentilin, L., Hoffman, N.E., Powers, J.C., Ottiger, I., Parikh, S., Kulczycki, A.M., Hurst, M., Ring, N., Wang, T., et al. Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy. J. Am. Coll. Cardiol. 66 (2015), 139–153.
63. 63 Pleger, S.T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med., 3, 2011, 92ra64.
64. 64 Ishikawa, K., Fish, K.M., Tilemann, L., Rapti, K., Aguero, J., Santos-Gallego, C.G., Lee, A., Karakikes, I., Xie, C., Akar, F.G., et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol. Ther. 22 (2014), 2038–2045.
65. 65 Carpentier, A.C., Frisch, F., Labbé, S.M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., Gaudet, D., Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97 (2012), 1635–1644.
66. 66 Gaudet, D., Stroes, E.S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S.J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. Hum. Gene Ther. 27 (2016), 916–925.
67. 67 Viney, N.J., van Capelleveen, J.C., Geary, R.S., Xia, S., Tami, J.A., Yu, R.Z., Marcovina, S.M., Hughes, S.G., Graham, M.J., Crooke, R.M., et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388 (2016), 2239–2253.
68. 68 Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B.R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J.D., Taubel, J., Brooks, A., et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N. Engl. J. Med. 376 (2017), 41–51.
69. 69 Gaudet, D., Alexander, V.J., Baker, B.F., Brisson, D., Tremblay, K., Singleton, W., Geary, R.S., Hughes, S.G., Viney, N.J., Graham, M.J., et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N. Engl. J. Med. 373 (2015), 438–447.
70. 70 Thomas, G.S., Cromwell, W.C., Ali, S., Chin, W., Flaim, J.D., Davidson, M., Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62 (2013), 2178–2184.
71. 71 Wacker, B.K., Dronadula, N., Zhang, J., Dichek, D.A., Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 37 (2017), 316–327.
72. 72 Ylä-Herttuala, S., Palinski, W., Rosenfeld, M.E., Parthasarathy, S., Carew, T.E., Butler, S., Witztum, J.L., Steinberg, D., Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84 (1989), 1086–1095.
73. 73 Mäkinen, P.I., Lappalainen, J.P., Heinonen, S.E., Leppänen, P., Lähteenvuo, M.T., Aarnio, J.V., Heikkilä, J., Turunen, M.P., Ylä-Herttuala, S., Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc. Res. 88 (2010), 530–538.
74. 74 Tsimikas, S., Miyanohara, A., Hartvigsen, K., Merki, E., Shaw, P.X., Chou, M.Y., Pattison, J., Torzewski, M., Sollors, J., Friedmann, T., et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58 (2011), 1715–1727.
75. 75 DeYoung, M.B., Dichek, D.A., Gene therapy for restenosis: are we ready?. Circ. Res. 82 (1998), 306–313.
76. 76 Kutryk, M.J., Foley, D.P., van den Brand, M., Hamburger, J.N., van der Giessen, W.J., deFeyter, P.J., Bruining, N., Sabate, M., Serruys, P.W., ITALICS Trial. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. 39 (2002), 281–287.
77. 77 Turunen, P., Puhakka, H.L., Heikura, T., Romppanen, E., Inkala, M., Leppänen, O., Ylä-Herttuala, S., Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. Hum. Gene Ther. 17 (2006), 405–414.
78. 78 George, S.J., Wan, S., Hu, J., MacDonald, R., Johnson, J.L., Baker, A.H., Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 124:11, Suppl (2011), S135–S142.
79. 79 Conte, M.S., Bandyk, D.F., Clowes, A.W., Moneta, G.L., Seely, L., Lorenz, T.J., Namini, H., Hamdan, A.D., Roddy, S.P., Belkin, M., et al., PREVENT III Investigators. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43 (2006), 742–751 discussion 751.
80. 80 Alexander, J.H., Hafley, G., Harrington, R.A., Peterson, E.D., Ferguson, T.B. Jr., Lorenz, T.J., Goyal, A., Gibson, M., Mack, M.J., Gennevois, D., et al., PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294 (2005), 2446–2454.
81. 81 Ark Therapeutics. (2009) Ark Therapeutics completes potency test qualification enabling Trinam Phase III trial to begin. Quick Facts RTTNews. 8.1.2009.
82. 82 Rissanen, T.T., Ylä-Herttuala, S., Current status of cardiovascular gene therapy. Mol. Ther. 15 (2007), 1233–1247.
83. 83 Karvinen, H., Pasanen, E., Rissanen, T.T., Korpisalo, P., Vähäkangas, E., Jazwa, A., Giacca, M., Ylä-Herttuala, S., Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther. 18 (2011), 1166–1172.
84. 84 Korpisalo, P., Hytönen, J.P., Laitinen, J.T., Laidinen, S., Parviainen, H., Karvinen, H., Siponen, J., Marjomäki, V., Vajanto, I., Rissanen, T.T., Ylä-Herttuala, S., Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy. Eur. Heart J. 32 (2011), 1664–1672.